Loading clinical trials...

Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder

A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Adjunctive Aripiprazole Therapy in the Treatment of Mania in Bipolar I Disorder Patients Treated on Valproate or Lithium and in Need of Further Clinical Improvement

NCT00665366•Otsuka Pharmaceutical Development & Commercialization, Inc.

View on ClinicalTrials.gov

Summary

The purpose of the study is to determine whether aripiprazole provides additional clinical benefit to patients with Bipolar I disorder when combined with lithium or valproate over 12 weeks.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Clinical diagnosis of bipolar I disorder mania, manic or mixed episode, with or without psychotic features
•Current ongoing lithium or valproate treatment with the possibility of benefiting, based on the investigator's clinical judgment, from adjunctive treatment with aripiprazole
•Therapeutic serum levels of lithium or valproate and a Young Mania Rating Total Score of 16 or higher at screening and baseline
•Participants taking current lithium or valproate treatment combined with antipsychotic medication other than aripiprazole are acceptable, provided that the other antipsychotic medication is washed out at least 3 days prior to the blood draw for therapeutic plasma levels of lithium and valproate determination. Long-acting antipsychotics must be washed out prior to entering the double-blind treatment.

Exclusion Criteria

•Women of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 4 weeks after the last dose of investigational product
•A diagnosis of delirium, dementia, amnesia or other cognitive disorder, or a psychotic disorder
•Current diagnosis of delirium, dementia, a cognitive disorder (ie, amnesia), or a psychotic disorder (ie, schizophrenia or schizoaffective disorder)
•Current diagnosis of bipolar II disorder, bipolar disorder not otherwise specified, or any other primary psychiatric disorder other than bipolar I disorder mania
•Thyroid pathology
•Demonstrated cocaine abuse or dependence within the past 3 months prior to screening.
•History of neuroleptic malignant syndrome from antipsychotic agents
•Manic symptoms that investigator considers refractory to treatment
•Previous nonresponsive (by investigator judgment) to aripiprazole for manic symptoms
•Significant risk of suicide based on history, mental status exam, or investigator judgment.

Locations (73)

Local Institution

Salzburg, Austria

Local Institution

Vienna, Austria

Local Institution

Hradec Králové, Czechia

Local Institution

Litoměřice, Czechia

Local Institution

Prague, Czechia

Local Institution

Prague, Czechia

Local Institution

Prague, Czechia

Local Institution

Beaupuy, France

Local Institution

Brumath, France

Local Institution

Château-Gontier, France

Key Dates

Start Date

June 1, 2008

Primary Completion Date

October 1, 2011

Completion Date

October 1, 2011

Last Updated

December 2, 2013

Enrollment

493

ACTUAL participants

Conditions

Bipolar Disorder Mania

Interventions

Aripiprazole

DRUG

Placebo

DRUG

Lithium

DRUG

Valproate

DRUG